[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351576-105":59,"doc-detail-351576-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-microbiome-modulating-strategies-in-cancer-patients-receiving-immunotherapy-msit-a-systematic-review-and-metaanalysis","Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT) - A systematic review and metaanalysis","","Microbiome-modulating strategies (MMSs) such as probiotics, synbiotics, and faecal microbiota transplantation (FMT) are investigated as adjuncts to immune checkpoint inhibitors (ICIs), while clinical benefits remain uncertain. A systematic review of PubMed, Embase, and CENTRAL through February 2025 identified 36 studies (25 trials/cohorts; n=2,746) and pooled efficacy, microbiome shifts, and safety. MMS plus ICIs showed an overall objective response rate of 40% and mostly low-grade adverse events, with responders enriched for short-chain fatty acid-producing taxa and Bifidobacterium.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-microbiome-modulating-strategies-in-cancer-patients-receiving-immunotherapy-msit-a-systematic-review-and-metaanalysis/351576/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-microbiome-modulating-strategies-in-cancer-patients-receiving-immunotherapy-msit-a-systematic-review-and-metaanalysis/351576.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which MMS approaches were evaluated for cancer patients receiving ICIs?","Question",{"text":112,"@type":113},"The review focuses on microbiome-modulating strategies including probiotics, synbiotics, and faecal microbiota transplantation (FMT) used alongside immune checkpoint inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the pooled objective response rate when MMS was combined with ICIs?",{"text":117,"@type":113},"MMS combined with ICIs yielded a pooled objective response rate (ORR) of 40% (95% CI: 31%–49%), based on included clinical studies.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety patterns were reported for MMS-related adverse events?",{"text":121,"@type":113},"Adverse events related to MMS were mostly grade 1–2, with severe events reported as rare in the limited pooled sample described.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351576,1790678649,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nImpact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT):  \nA systematic review and metaanalysis  \nMay Soe Thu1, Ho Bao Chau Le1,2, Nguyen Phuc Duc1,2, Van Hieu Mai3,4, Nina Walker5 & Nattiya Hirankarn1􀀍  \nThe gut microbiota influences immune checkpoint inhibitors (ICIs) efficacy. Microbiome-modulating strategies (MMSs), including probiotics, synbiotics, and faecal microbiota transplantation (FMT), have emerged as promising adjuncts, but their clinical impact remains uncertain. We systematically reviewed PubMed, Embase, and CENTRAL to February 2025 for clinical cohorts evaluating MMS in cancer patients receiving ICIs. Thirty-six studies (25 trials/cohorts; n = 2,746) were included. Metaanalyses, and subgroup analyses were performed for efficacy along with microbiome shifts and safety. MMS plus ICIs achieved a pooled objective response rate (ORR) of 40%(95% CI: 31%–49%; I² = 63.4%; p = 0.0003; 95% PI: 15%–72%). Descriptive proportions showed ORR of 45%(95% CI: 32%–58%; I² = 72.5%; p = 0.0058) for probiotics and 33%(95% CI: 22%–48%; I² = 60.7%; p = 0.0064) for FMT; however, these findings are non-comparative and confounded by study differences. Exploratory subgroup signals were noted for probiotics in NSCLC (ORR 55%; 95%CI: 45%–64%; I² = 0%; p = 0.3683) and FMTin melanoma (ORR 39%; 95% CI: 15%–69%; I² = 72.5%; p = 0.0262) . Dual ICI regimens showed the highest point estimate for ORR (43%; 95% CI: 17%–73%; I² = 68.5%; p = 0.0747) but increased toxicity. Microbiome analyses revealed enrichment of short-chain fatty acid-producing taxa and Bifidobacterium spp. among responders. Based on a limited pooled sample size (n = 143), MMS-related adverse events were mostly grade 1–2 (42%; 95% CI: 14%–77%, I² = 53.8%, p = 0.0210), with rare severe events (1%) .  \nOverall, MMS show promising, though preliminary, hypothesis-generating signals for modulating ICI response. Given high heterogeneity and reliance on early-phase, single-arm trials, the findings underscore urgent need for large, biomarker-driven randomized controlled trials to define optimal interventions and cautiously integrate microbiome modulation into immuno-oncology care.  \nKeywords Microbiome, Probiotics, Faecal microbiota transplantation, Immunotherapy, Immune checkpoint inhibitors  \nAbbreviations  \nCENTRAL CIs PRISMA-PRCTs  \nUS  \nCochrane central register of controlled trials  \nConfidence intervals  \nPreferred reporting items for systematic review and meta-analysis protocols Randomized controlled trials  \nUnited States  \n1Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 2Graduate Program in Medical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 3Graduate Program in Clinical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 4Department of Molecular Biology and Genetics, Faculty of Medicine, University of Health Sciences, Vietnam National University Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam. 5Master Program of Biological Sciences, School of Biosciences, University of Liverpool, Liverpool L69 7ZX, UK. 􀀍 email: [Nattiya.H@chula.ac.th](Nattiya.H@chula.ac.th); [nattiyap@gmail.com](nattiyap@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nCancer remains a significant global health burden, accounting for more than 9.7 million deaths in 20221. Advances in immuno-oncology, particularly the development of immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), have transformed the therapeutic landscape across multiple malignancies2–4. Despite these advances, the proportion of patients who derive durable benefits remains modest. In non-sma","cbCailbf7OxZIBvn","https://ap.wps.com/l/cbCailbf7OxZIBvn","pdf",4369598,18,"English","# Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT)\n## Systematic review and metaanalysis methods\n## Efficacy outcomes: objective response rate\n## Subgroup signals and regimen comparisons\n## Microbiome changes and safety profile\n## Conclusions and need for future trials","[{\"question\":\"Which MMS approaches were evaluated for cancer patients receiving ICIs?\",\"answer\":\"The review focuses on microbiome-modulating strategies including probiotics, synbiotics, and faecal microbiota transplantation (FMT) used alongside immune checkpoint inhibitors.\"},{\"question\":\"What was the pooled objective response rate when MMS was combined with ICIs?\",\"answer\":\"MMS combined with ICIs yielded a pooled objective response rate (ORR) of 40% (95% CI: 31%–49%), based on included clinical studies.\"},{\"question\":\"What safety patterns were reported for MMS-related adverse events?\",\"answer\":\"Adverse events related to MMS were mostly grade 1–2, with severe events reported as rare in the limited pooled sample described.\"}]","Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT) - A systematic review and metaanalysis | PDF",1790094776,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c48965782b6c5a1593c01ff260c0d1d2.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5a6d4f1c50b0ad5284233c0c1ceee02.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1f87a3fbfaafbdea8e68d320d2ba796.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/001dd2f5bb3b74e27806ea8711d24d61.webp",980,1287]